GPT and metabolic dysfunction-associated steatotic liver disease: In contrast, a 3-month retrospective observational study of 38 NAFLD patients revealed that pemafibrate significantly decreased ALT, GGT, and TG levels and NAFLD fibrosis score [27] and increased HDL-cholesterol levels [17].